ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Soleno Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Soleno common stock between March 26, 2025, and November 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 5, 2026 [3] - The lawsuit claims that Soleno made false or misleading statements regarding the safety and commercial viability of its drug DCCR, which could lead to significant investor damages [5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4] - The firm has been recognized for its achievements in securities class action settlements, including a notable $438 million recovery for investors in 2019 [4]